131 related articles for article (PubMed ID: 2525079)
1. Protective effects of ONO 3708, a new thromboxane A2 receptor antagonist, during experimental endotoxin shock.
Taneyama C; Sasao J; Senna S; Kimura M; Kiyono S; Goto H; Arakawa K
Circ Shock; 1989 May; 28(1):69-77. PubMed ID: 2525079
[TBL] [Abstract][Full Text] [Related]
2. Effects of ONO-3708, an antagonist of the thromboxane A2/prostaglandin endoperoxide receptor, on platelet aggregation and thrombosis.
Kondo K; Seo R; Naka M; Kitagawa T; Wakitani K; Sakata M; Kira H; Okegawa T; Kawasaki A
Eur J Pharmacol; 1989 Apr; 163(2-3):253-61. PubMed ID: 2721574
[TBL] [Abstract][Full Text] [Related]
3. [The effects of ONO 3708, a new thromboxane receptor antagonist, on cardiovascular response during the early phases of endotoxin shock in anesthetized dogs].
Sasao J; Taneyama C; Kimura M; Kiyono S
Masui; 1989 Sep; 38(9):1188-94. PubMed ID: 2810716
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of ONO-3708 and S-145 on shape change and aggregation of rabbit platelets induced by STA2.
Li BY; Qiao GF; Sun JP; Gao YR; Li WH
Zhongguo Yao Li Xue Bao; 1996 Jul; 17(4):345-8. PubMed ID: 9812720
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic characterization of human and canine thromboxane A2/prostaglandin H2 receptors in platelets and blood vessels: evidence for different receptors.
Mais DE; Saussy DL; Chaikhouni A; Kochel PJ; Knapp DR; Hamanaka N; Halushka PV
J Pharmacol Exp Ther; 1985 May; 233(2):418-24. PubMed ID: 2987481
[TBL] [Abstract][Full Text] [Related]
6. Phenol red is a thromboxane A2/prostaglandin H2 receptor antagonist in canine lingual arteries and human platelets.
Greenberg SS; Johns A; Kleha J; Xie J; Wang Y; Bianchi J; Conley K
J Pharmacol Exp Ther; 1994 Mar; 268(3):1352-61. PubMed ID: 8138950
[TBL] [Abstract][Full Text] [Related]
7. The novel prostaglandin I2 mimetic ONO-1301 escapes desensitization in an antiplatelet effect due to its inhibitory action on thromboxane A2 synthesis in mice.
Kashiwagi H; Yuhki K; Kojima F; Kumei S; Takahata O; Sakai Y; Narumiya S; Ushikubi F
J Pharmacol Exp Ther; 2015 May; 353(2):269-78. PubMed ID: 25740898
[TBL] [Abstract][Full Text] [Related]
8. The effect of inhaled anesthetics on the platelet aggregation and the ligand-binding affinity of the platelet thromboxane A2 receptor.
Hirakata H; Ushikubi F; Narumiya S; Hatano Y; Nakamura K; Mori K
Anesth Analg; 1995 Jul; 81(1):114-8. PubMed ID: 7598237
[TBL] [Abstract][Full Text] [Related]
9. The effects of prostacyclin (PGI2) on endotoxin shock and endotoxin-induced platelet aggregation in dogs.
Fletcher JR; Ramwell PW
Circ Shock; 1980; 7(3):299-308. PubMed ID: 7004660
[TBL] [Abstract][Full Text] [Related]
10. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo.
De Clerck F; Beetens J; Van de Water A; Vercammen E; Janssen PA
Thromb Haemost; 1989 Feb; 61(1):43-9. PubMed ID: 2526385
[TBL] [Abstract][Full Text] [Related]
11. Antiplatelet effects of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e] oxepine-2-carboxylate monohydrate.
Karasawa A; Kawakage M; Shirakura S; Higo K; Kubo K; Ohshima E; Obase H
Arzneimittelforschung; 1991 Dec; 41(12):1230-6. PubMed ID: 1840011
[TBL] [Abstract][Full Text] [Related]
12. Effects of a new thromboxane A2-antagonist (ONO-3708) and a new leukotriene-antagonist (ONO-1078) on thromboxane A2 analogue-, leukotriene C4-, and D4-induced regional myocardial blood flow reduction.
Torii T; Toki Y; Hieda N; Ito Y; Okumura K; Hashimoto H; Ito T; Ogawa K; Satake T
Heart Vessels; 1988; 4(2):104-11. PubMed ID: 3253270
[TBL] [Abstract][Full Text] [Related]
13. Thromboxane-blocked swine as an experimental model of severe intravascular inflammation and septic shock.
Jesmok G; Gundel R
Shock; 1995 Nov; 4(5):379-83. PubMed ID: 8595527
[TBL] [Abstract][Full Text] [Related]
14. [Experimental study on the pathophysiology of endotoxin shock as analysed by alterations in thromboxane B2 and 6-keto-PGF1 alpha levels].
Baba H
Nihon Geka Gakkai Zasshi; 1988 Jan; 89(1):6-20. PubMed ID: 3283521
[TBL] [Abstract][Full Text] [Related]
15. Protective effects of trans-13-APT, a thromboxane receptor antagonist, in endotoxemia.
Olanoff LS; Cook JA; Eller T; Knapp DR; Halushka PV
J Cardiovasc Pharmacol; 1985; 7(1):114-20. PubMed ID: 2580129
[TBL] [Abstract][Full Text] [Related]
16. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D
Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331
[TBL] [Abstract][Full Text] [Related]
17. Effects of ONO-3708, an antagonist of the thromboxane A2/prostaglandin endoperoxide receptor, on blood vessels.
Kondo K; Seo R; Omawari N; Imawaka H; Wakitani K; Kira H; Okegawa T; Kawasaki A
Eur J Pharmacol; 1989 Sep; 168(2):193-200. PubMed ID: 2606148
[TBL] [Abstract][Full Text] [Related]
18. Prostaglandin H2/thromboxane A2 pathway in platelet aggregation and activity of Dahl salt-sensitive rat--a sulotroban study.
Somova L
Methods Find Exp Clin Pharmacol; 1996 Jun; 18(5):309-13. PubMed ID: 8817465
[TBL] [Abstract][Full Text] [Related]
19. Thromboxane A2 receptor characterization in human astrocytoma cells and rabbit platelets by a new thromboxane antagonist, [3H]ONO NT-126.
Takano S; Ishimoto H; Nakahata N; Nakanishi H
Res Commun Chem Pathol Pharmacol; 1992 May; 76(2):155-70. PubMed ID: 1534919
[TBL] [Abstract][Full Text] [Related]
20. Protective effects of a combination thromboxane synthesis inhibitor-receptor antagonist, R-68070, during murine traumatic shock.
Aoki N; Johnson G; Siegfried MR; Lefer AM
Eicosanoids; 1989; 2(3):169-74. PubMed ID: 2534278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
